TD Cowen Lifts GLP-1 Market Outlook, Sees Global Sales Reaching $150 Billion by 2030

ozempic value nonaccomplishment drugs GLP-1 NEW SIZE ©chemist4u

TD Cowen has raised its semipermanent forecast for the planetary GLP-1 market, projecting yearly income of diabetes and obesity treatments successful the class volition scope $150 cardinal by 2030.

The revised estimation marks an summation from the firm's erstwhile forecast of $139 billion, reflecting stronger expectations for diligent adoption and continued enlargement of the market.

Patient Numbers Expected to Grow Significantly

The brokerage present anticipates that astir 59 cardinal radical worldwide volition beryllium utilizing GLP-1 therapies by the extremity of the decade.

That compares with its earlier projection of 46 cardinal patients, highlighting expectations for broader entree to attraction and expanding request for weight-management and diabetes medications.

According to TD Cowen, maturation successful diligent volumes should much than offset pricing pressures expected crossed the sector.

Lower Prices Seen Driving Wider Adoption

The steadfast noted that aboriginal terms reductions are apt to beryllium accompanied by important increases successful attraction uptake.

As manufacturers grow accumulation capableness and contention intensifies, little pricing could assistance marque GLP-1 therapies accessible to a larger diligent population, supporting continued marketplace maturation contempt imaginable unit connected gross per prescription.

Oral Treatments Poised to Capture Larger Share

TD Cowen besides upgraded its outlook for oral GLP-1 medications, which are expected to go an progressively important conception of the market.

The steadfast present forecasts that oral formulations volition relationship for 14% of planetary GLP-1 income by 2030, compared with its erstwhile estimation of 11%.

The increasing relation of pill-based treatments reflects expectations that immoderate patients and healthcare providers volition favour oral alternatives implicit injectable therapies erstwhile clinically appropriate.

Eli Lilly and Novo Nordisk Expected to Remain Dominant

Despite the accomplishment of caller competitors, TD Cowen expects the marketplace to stay heavy concentrated among the existent manufacture leaders.

Eli Lilly (NYSE:LLY) is projected to clasp astir 62% of the planetary GLP-1 marketplace by worth successful 2030, portion Novo Nordisk (NYSE:NVO) is expected to relationship for astir 31%.

Together, the 2 pharmaceutical companies are forecast to power the overwhelming bulk of manufacture income arsenic request for obesity and diabetes treatments continues to accelerate worldwide.

Obesity and Diabetes Markets Continue to Expand

The revised forecast underscores increasing assurance successful the semipermanent imaginable of GLP-1 therapies, which person transformed attraction options for some Type 2 diabetes and obesity.

With diligent adoption expected to summation substantially implicit the coming years, the assemblage remains 1 of the fastest-growing areas wrong the planetary pharmaceutical industry.

Eli Lilly banal terms

Novo Nordisk banal terms